Stockscreener 앱 받기
26.48
1.43%
-0.39
전일 마감가:
$26.87
열려 있는:
$26.825
하루 거래량:
3.05M
Relative Volume:
0.82
시가총액:
$19.67B
수익:
$956.00K
순이익/손실:
$-221.32M
주가수익비율:
-82.75
EPS:
-0.32
순현금흐름:
$-142.25M
1주 성능:
-5.65%
1개월 성능:
+4.27%
6개월 성능:
+23.94%
1년 성능:
+138.17%
1일 변동 폭
$26.38
$27.64
1주일 범위
$24.16
$29.36
52주 변동 폭
$11.07
$36.91
Summit Therapeutics Inc Stock (SMMT) Company Profile
명칭
Summit Therapeutics Inc
전화
305-203-2034
주소
601 BRICKELL KEY DRIVE, MIAMI
SMMT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
26.48 | 19.08B | 956.00K | -221.32M | -142.25M | -0.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.00 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
566.35 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.72 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
652.80 | 39.02B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
309.38 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-01 | 개시 | UBS | Buy |
| 2025-06-11 | 개시 | Leerink Partners | Underperform |
| 2025-03-26 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-03-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-03-12 | 개시 | Evercore ISI | Outperform |
| 2025-02-28 | 개시 | Goldman | Buy |
| 2025-01-08 | 개시 | Truist | Buy |
| 2024-12-11 | 개시 | Wells Fargo | Overweight |
| 2024-12-06 | 개시 | Jefferies | Buy |
| 2024-11-04 | 개시 | JMP Securities | Mkt Outperform |
| 2024-09-27 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-08-12 | 개시 | H.C. Wainwright | Buy |
| 2024-05-07 | 개시 | Citigroup | Buy |
| 2024-03-26 | 개시 | Stifel | Buy |
| 2018-06-28 | 다운그레이드 | Janney | Buy → Neutral |
| 2018-05-02 | 개시 | Janney | Buy |
| 2018-04-12 | 재확인 | Needham | Buy |
| 2018-02-13 | 개시 | BTIG Research | Buy |
| 2018-01-04 | 개시 | SunTrust | Buy |
| 2017-12-01 | 재개 | H.C. Wainwright | Buy |
| 2016-11-16 | 재확인 | RBC Capital Mkts | Outperform |
| 2016-10-05 | 재확인 | Needham | Buy |
| 2016-09-16 | 개시 | H.C. Wainwright | Buy |
| 2015-03-30 | 개시 | Needham | Buy |
| 2015-03-30 | 개시 | Oppenheimer | Outperform |
모두보기
Summit Therapeutics Inc 주식(SMMT)의 최신 뉴스
Ivonescimab Data from Global Phase III HARMONi Study to be Showcased at Presidential Symposium at WCLC 2025 - Stock Titan
Custom Dashboard Highlights Summit Therapeutics Inc. Price MomentumJuly 2025 Technicals & Reliable Intraday Trade Plans - beatles.ru
Summit Therapeutics Pullback Seen as 'Overreaction' Amid Liquidity Options, Truist Says - 富途牛牛
Summit Therapeutics (SMMT) Nosedives 9% on Dismal Earnings, Absence of Investor Call - Yahoo Finance
A Quick Look at Today's Ratings for Summit Therapeutics(SMMT.US), With a Forecast Between $33 to $35 - 富途牛牛
Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (SMMT) and Glaukos (GKOS) - The Globe and Mail
Summit Therapeutics Faces Questions Over Its Cash Burn And Future - Finimize
SMMT Q2 Loss Wider Than Expected, Ivonescimab Studies in Focus - TradingView
Evercore ISI Group Raises Summit Therapeutics PT to $34, Maintains Outperform Rating - AInvest
Summit Therapeutics stock price target raised to $34 by Evercore ISI - Investing.com Canada
Summit Therapeutics shares fall 3.72% premarket after reporting Q2 financial results and operational updates. - AInvest
Summit Therapeutics Inc. Securities Fraud LawsuitClass Action Opportunity - AInvest
SMMT Investors Have Opportunity to Lead Summit Therapeutics Inc. Securities Fraud Lawsuit with the Schall Law Firm - Barchart.com
Summit Therapeutics Reports Q2 2025 Progress and Financials - TipRanks
Summit Therapeutics Q2 Loss Widens to $0.12 per Share - AInvest
Summit Therapeutics Q2 Adjusted Loss Widens - MarketScreener
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2025 - Placera.se
Summit Therapeutics Amends Stock Distribution Agreement - TipRanks
Earnings Flash (SMMT) Summit Therapeutics Inc. Posts Q2 Adjusted Loss $0.12 per Share, vs. FactSet Est of $-0.10 - MarketScreener
Summit Therapeutics Inc. SEC 10-Q Report - TradingView
Pattern recognition hints at Summit Therapeutics Inc. upsideFree AI Driven Stock Trend Forecast - Newser
Visual trend scoring systems applied to Summit Therapeutics Inc.Free Weekly Stock Watch With Growth Focus - Newser
Summit Therapeutics Inc. recovery potential after sell offChart Driven Entry Timing for Swing Trades - Newser
Summit Therapeutics Advances in Metastatic Colorectal Cancer Treatment with Phase II Trial - TipRanks
Traders Buy Large Volume of Call Options on Summit Therapeutics (NASDAQ:SMMT) - Defense World
ETFs and Analyst Targets: iShares Russell 1000 Growth ETF has 10% Upside - AInvest
Summit Therapeutics' Flawed Buy Thesis and the Missing Link in Oncology Data - AInvest
Summit Therapeutics: Flawed Buy Thesis Explained - AInvest
Summit Therapeutics: Here Are (Some Of) The Reasons The Buy Thesis Is Flawed (NASDAQ:SMMT) - Seeking Alpha
Published on: 2025-08-05 22:22:23 - Newser
Cwm LLC Increases Position in Summit Therapeutics PLC (NASDAQ:SMMT) - Defense World
Using data tools to time your Summit Therapeutics Inc. exitTrend Analysis for Safer Market Entries - Newser
Using portfolio simulators with Summit Therapeutics Inc. includedTechnical Reversal Setup with Risk Limits - Newser
Best data tools to analyze Summit Therapeutics Inc. stockFast Movement Forecast for Trading Success - Newser
Institutional scanner results for Summit Therapeutics Inc.Volume Spike Detection for Early Breakouts - Newser
Summit Therapeutics Q3 2024 slides: Ivonescimab shows superior PFS vs. pembrolizumab - Investing.com Canada
Published on: 2025-08-04 09:17:43 - metal.it
Summit Therapeutics Skyrockets 7.22% – What’s Fueling This Biotech Surge? - AInvest
Advanced analytics toolkit walkthrough for Summit Therapeutics Inc.Weekly Price Target Forecast and Alerts - Newser
How hedge fund analytics apply to Summit Therapeutics Inc. stockHigh Conviction Stock Long-Term Summary - Newser
How volatile is Summit Therapeutics Inc. stock compared to the marketDiscover breakthrough stocks with expert help - Jammu Links News
Is Summit Therapeutics Inc. stock a growth or value playMarket Liquidity and Price Flow Analysis - Newser
What analysts say about Summit Therapeutics Inc. stockRecord-breaking gains - Jammu Links News
What is Summit Therapeutics Inc. company’s growth strategyBuild a diversified portfolio for steady growth - Jammu Links News
2 Beaten-Down Stocks With Incredible Upside Potential - The Motley Fool
Why is Summit Therapeutics Inc. stock attracting strong analyst attentionTremendous growth opportunities - Jammu Links News
Published on: 2025-08-03 16:05:04 - Jammu Links News
How does Summit Therapeutics Inc. generate profit in a changing economyExtraordinary profit generation - Jammu Links News
Does Summit Therapeutics Inc. stock perform well during market downturnsSuperior return velocity - Jammu Links News
What are the latest earnings results for Summit Therapeutics Inc.Capitalize on market momentum for big wins - Jammu Links News
Can Summit Therapeutics Inc. rally from current levelsLow Drawdown Picks with Weekly Updates - newser.com
Summit Therapeutics Inc (SMMT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Summit Therapeutics Inc 주식 (SMMT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| DUGGAN ROBERT W | Co-Chief Executive Officer |
May 30 '25 |
Option Exercise |
2.64 |
74,545 |
196,799 |
555,754,696 |
0.60%
0.01%
자본화:
|
볼륨(24시간):